PP_1170x120_10-25-21

Abbvie’s Trilpix.

Aurobindo gets FDA approval for fenofibric acid delayed-release capsules

Aurobindo gets FDA approval for fenofibric acid delayed-release capsules

EAST WINDSOR, N.J. – Aurobindo has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid delayed-release capsules, 45 mg and 135 mg. Aurobindo’s fenofibric acid delayed-release capsules is an AB-rated generic equivalent to the reference listed drug, Abbvie’s Trilpix. Fenofibric acid delayed-release capsules are peroxisome proliferator-activated